MONSEY, N.Y., May 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $43.00 per share in cash for which Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics”) has agreed to be sold to GTCR, a leading private equity firm. The sales price is far below the price targets for Surmodics of at least two Wall Street analysts (source: TipRanks).
If you remain a Surmodics shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:
https://wohlfruchter.com/cases/surmodics/
Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com.
Why is there an investigation?
On May 29, 2024, Surmodics announced that it had agreed to be sold to GTCR for $43.00 per share in cash.
“We are investigating whether the Surmodics Board of Directors acted in the best interests of Surmodics shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Surmodics shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”
Notably, according to TipRanks, the sales price of $43.00 per share is far below the price target for Surmodics of:
- Brooks O’Neil of Lake Street ($75.00)
- Michael Petusky of Barrington ($71.00)
About Wohl & Fruchter
Wohl & Fruchter LLP has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
alerts@wohlfruchter.com
www.wohlfruchter.com
Source:
Wohl & Fruchter LLP2024 GlobeNewswire, Inc., source Press Releases
SURMODICS, INC. 
